Premium
Cognition‐Enhancing Drugs
Author(s) -
MEHLMAN MAXWELL J.
Publication year - 2004
Publication title -
the milbank quarterly
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 101
eISSN - 1468-0009
pISSN - 0887-378X
DOI - 10.1111/j.0887-378x.2004.00319.x
Subject(s) - cognition , psychology , risk analysis (engineering) , cognitive psychology , business , psychiatry
New drugs that enhance cognition in cognitively healthy individuals present difficult public policy challenges. While their use is not inherently unethical, steps must be taken to ensure that they are safe, that they are widely available to promote equality of opportunity, and that individuals are free to decide whether or not to use them.